Research Article
Detection of Mutations in the 81 Bp RRDR of Rpob Gene in Mycobacterium Tuberculosis Clinical Isolates Using Xpert®MTB/RIF in Basra/Iraq
@INPROCEEDINGS{10.4108/eai.7-9-2021.2314814, author={Ghorob S Khudhair and Khairallah A.S Mohammed and Dheyaa Bekheet Al-Rabeai}, title={Detection of Mutations in the 81 Bp RRDR of Rpob Gene in Mycobacterium Tuberculosis Clinical Isolates Using Xpert®MTB/RIF in Basra/Iraq}, proceedings={Proceedings of 2nd International Multi-Disciplinary Conference Theme: Integrated Sciences and Technologies, IMDC-IST 2021, 7-9 September 2021, Sakarya, Turkey}, publisher={EAI}, proceedings_a={IMDC-IST}, year={2022}, month={1}, keywords={rifampicin-resistance rpob xpert® mtb/rif assay basra}, doi={10.4108/eai.7-9-2021.2314814} }- Ghorob S Khudhair
Khairallah A.S Mohammed
Dheyaa Bekheet Al-Rabeai
Year: 2022
Detection of Mutations in the 81 Bp RRDR of Rpob Gene in Mycobacterium Tuberculosis Clinical Isolates Using Xpert®MTB/RIF in Basra/Iraq
IMDC-IST
EAI
DOI: 10.4108/eai.7-9-2021.2314814
Abstract
Xpert®️ MTB/RIF assay is presently used in Iraq for the detection of rifampicin resistance Mycobacterium tuberculosis (MTB) isolates. Rifampicin resistance is determined based on any mutation in the Rifampicin Resistant Determinant Region (RRDR) of the rpoB gene using five overlapping probes (A, B, C, D, E). In this study, data were collected from specimens received and tested using conventional methods and Xpert®️ MTB/RIF assay at the Advisory Clinic for Chest Diseases and Respiratory in Basra province from January 2016 to December 2020. Among the 2542 positive samples for MTB, rifampicin resistance was detected in 57 (2.24%) specimens, of which full data for 44 RR–TB patients is available. Of the 44 RR-TB patients, 35 (79.5%) were retreatment cases, and the most common rpoB mutations were in the region of Probe E (70.5%), followed by Probe B (11.3%), Probe A, and D (9.1%) for each. Mutations in Probe C were not observed.
